28X Secures £1.5m For Privacy-First Women's Health Platform

Amber Vodegel, the founder who previously sold Pregnancy+ to Philips, has secured an estimated £1.5m for her new venture, 28x Ltd. The London-based company, which trades as 28X, reached an estimated post-money valuation of £5.6m following the allotment of shares on 5 September 2025. The funding details were made public in a filing dated 4 May 2026.

28X is a women's health platform that prioritises data privacy through the use of on-device artificial intelligence. Unlike many health applications that rely on cloud storage, 28X processes all health data directly on the user's phone. This approach ensures that personal information never leaves the device, removing the possibility of server breaches or the sale of user data to third parties.

The company was incorporated on 9 December 2023 and currently employs 11 people. Its product is designed to be free for all users, moving away from the subscription-based models and paywalls that are common in the digital health sector. The platform has been clinically reviewed and is endorsed by NHS clinicians. It also holds a 92 percent rating from ORCHA, an organisation that evaluates the quality and safety of health apps.

The founder's previous success with Pregnancy+, which scaled to 150 million users before its acquisition, provides a background of experience in the maternal and women's health space. 28X is already live in the UK and is now focused on global scaling.

In addition to software development, the company's registered activities include human health services provided by paramedical practitioners and the operation of medical laboratories. The platform is intended to provide health education that is both private and accessible regardless of a user's financial situation.

While the specific investors for this £1.5m round were not named in the recent filing, the company has previously received support from the Philips Foundation. It is also backed by a group of 40 mission-aligned investors.

The estimated £5.6m valuation follows less than two years of operation. The company continues to operate from its headquarters in London, focusing on its mission to provide a health platform with no data harvesting or cloud-based surveillance.